01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Cigna Group's Q2 2024 report indicates a strong increase in total revenues, driven primarily by a significant rise in pharmacy revenues, reflecting growth from new clients and organic expansion within its Evernorth Health Services segment.
While total shareholders' net income saw a decrease year-over-year, largely due to a substantial impairment of equity securities in Q1 2024, the adjusted income from operations showed a healthy increase, demonstrating resilience in underlying business performance. The company's Cigna Healthcare segment experienced moderate revenue growth and improved profitability, supported by higher premium rates and expense management, though a slight decline in medical customers was noted. Liquidity remains robust with significant cash reserves and undrawn credit facilities.
The company continues to execute on its capital deployment strategy, including substantial share repurchases and the upcoming sale of its Medicare Advantage businesses, which is expected to yield approximately $3.7 billiona. Overall, Cigna appears to be navigating a dynamic healthcare landscape effectively, with core business segments showing operational strength despite market headwinds and one-time financial impacts.
02—Key points
Key Highlights
- Total revenues increased by 25% year-over-year to $60.5 billion, driven by a 33% surge in pharmacy revenues to $45.1 billion, primarily due to new clients and organic growth in Evernorth Health Services.
- Shareholders' net income decreased by 53% to $1.27 billion for the six months ended June 30, 2024, primarily impacted by a $1.8 billion impairment of equity securities in Q1 2024.
- Adjusted income from operations increased by 10% to $3.78 billion for the six months ended June 30, 2024, driven by strong performance in both Evernorth Health Services and Cigna Healthcare segments.
- The Cigna Healthcare segment reported a 4% increase in adjusted revenues and a notable 11% increase in pre-tax adjusted income from operations, benefiting from higher premium rates and improved expense ratios.
- Medical customers decreased by 2% to 19.04 million, primarily attributed to a decline in Individual and Family Plans customers within the Cigna Healthcare segment.
- The company entered into an agreement to sell its Medicare Advantage businesses to Health Care Service Corporation (HCSC) for approximately $3.7 billion, expected to close in Q1 2025, with proceeds primarily allocated to share repurchases.
- Liquidity is strong, with $7.0 billion in cash and short-term investments and $6.5 billion in undrawn committed capacity under revolving credit agreements.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Cigna Group kept $0.03.
- Revenue$60.52B100.0%
- Cost of revenue−$44.49B73.5%
- Gross profit$16.03B26.5%
- Operating costs−$13.62B22.5%
- Operating income$2.41B4.0%
- Interest, other & tax−$864.0M1.4%
- Net income$1.55B2.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $60.52B$48.59B | +24.6% |
| Cost of Revenue | $44.49B$33.44B | +33.0% |
| Gross Profit | $16.03B$15.14B | +5.9% |
| SG&A Expenses | $3.68B$3.43B | +7.3% |
| Operating Income | $2.41B$2.22B | +8.6% |
| Interest Expense | $378.00M$350.00M | +8.0% |
| Net Income | $1.55B$1.46B | +6.0% |
| EPS (Basic) | $5.51$4.96 | +11.1% |
| EPS (Diluted) | $5.45$4.92 | +10.8% |
| Shares Outstanding (Diluted) | 284.05M296.88M | −4.3% |
05—Questions
Frequently Asked Questions
What drove the significant increase in total revenues for the quarter?
Total revenues increased by 25% year-over-year to $60.5 billion, primarily driven by a substantial 33% increase in pharmacy revenues to $45.1 billion. This growth was largely attributed to new client acquisitions and organic growth within the Evernorth Health Services segment.
Why did Shareholders' Net Income decrease significantly in the first six months of the year, despite revenue growth?
Shareholders' net income for the six months ended June 30, 2024, decreased by 53% to $1.27 billion. This was significantly impacted by a $1.8 billion impairment of equity securities recognized in the first quarter of 2024, related to the company's investment in VillageMD. Adjusted income from operations, which excludes such non-recurring items, showed a healthy 10% increase, indicating underlying business strength.
What is the impact of the pending sale of Medicare Advantage businesses on the company's financial position?
Cigna Group has agreed to sell its Medicare Advantage and related businesses to HCSC for approximately $3.7 billion, expected to close in Q1 2025. The company anticipates using these proceeds to support its capital deployment priorities, primarily share repurchases, which is expected to enhance shareholder value. This divestiture is part of a strategic refocusing within the Cigna Healthcare segment.
How is the Cigna Healthcare segment performing, and what are the key trends?
The Cigna Healthcare segment demonstrated resilience with a 4% increase in adjusted revenues and an 11% rise in pre-tax adjusted income from operations for the six months ended June 30, 2024. This performance was supported by higher premium rates aimed at covering increasing medical costs and effective expense management, leading to a lower adjusted expense ratio. However, the segment saw a 2% decrease in total medical customers, mainly due to a decline in Individual and Family Plans.
06—Continue